Furmonertinib Incorporated into Linyi Medicare Catalogue

On April 13, Linyi City of Shandong Province officially rolled out the inclusive supplementary medical insurance program, “Linyi Medicare”, which exclusively targets those covered by the city’s medical insurance. With a premium of only 69 yuan a year, an applicant can enjoy up to 2 million yuan of medical expenditure compensation. Of particular note, patients with major and critical diseases need only bear a very small proportion of the treatment fees covered by the medical insurance program, with the rest reimbursed to reduce their economic burdens.



Furmonertinib, which just received approval for marketing last month, successfully made it into the city’s supplementary medical insurance catalogue. This is another endeavor by Allist dedicated to making medicines more widely available to patients in need and forging a diversified, innovative payment model following the steps of the Furmonertinib-based patient care program that it launched on March 23. Ms. Sandy Mu, CEO of Allist, said, “We are working together with our strategic partners at the moment to press ahead with our endeavor to make Furmonertinib part of the catalogues for national medical insurance, commercial insurance as well as local inclusive medical insurance programs. Resorting to the all-around, multi-layered medical insurance system, we seek to bring hope and benefits to more lung cancer patients in need with our Furmonertinib.”


What does Linyi Medicare insure against? Let’s look at an example




About Furmonertinib

Furmonertinib, the third generation epidermal growth factor receptor (EGFR) – tyrosine kinase inhibitors (TKI) that China self-developed with independent intellectual property rights, is indicated for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressive disease during or after prior treatments with EGFR-TKIs and who have confirmed EGFR T790M mutation, demonstrating dual activities, high selectivity, strong effect in tumor regression, and favorable safety.


About Allist

Shanghai Allist Pharmaceuticals Co., Ltd was founded in March, 2004. It is an innovation-oriented drug developer, producer and seller dedicated to oncotherapy that targets the demand of the global pharmaceutical market. With the philosophy of “advancing long life with innovative science and technology”, its primary mission is to create first-in-class and best-in-class medicines. After 17 years of unremitting efforts, Allist now enjoys comprehensive competitiveness, particularly the ability to produce, on an ongoing basis, the best anti-tumor drugs in the market with proved effect, in which it owns independent intellectual property rights.

On December 2, 2020, Shanghai Allist Pharmaceuticals Co., Ltd was listed on the STAR board of Shanghai Stock Exchange (Stock code: 688578).